Neuropsychiatric Drug Development (NDD)

Neuropsychiatric Drug Development (NDD) is organized by Hanson Wade and will be held from Jul 30 - Aug 01, 2018 at Courtyard by Marriott Boston Cambridge, Cambridge, Massachusetts, United States of America.

Globally it’s estimated 1 in 5 people suffer from neuropsychiatric disorders. This figure, combined with drugs that are showing little or no response is making neuropsychiatric disorders a huge unmet clinical need.

The neuropsychiatric drug development field has been stifled for decades by a lack of scientific progress in understanding the brain and costly and challenging clinical trials.

The tide is now starting to turn. Rapid scientific progress in identifying novel targets, discovering differentiated mechanisms of drug action and our ability to develop ‘fast acting’ therapeutics has brought renewed enthusiasm to the field and investment is pouring in.

Yet the lack of translatable animal models, costly clinical trials and difficulties in meeting clinical endpoints are preventing the field moving forward.

Developed with experts at Lundbeck , Roche, GSK and 20 other leading organisations, the inaugural Neuropsychiatric Drug Development Summit will enable you to solve the challenges in bringing next generation neuropsychiatric therapeutics to market.

Prices:
Gold: Conference And 2 workshops: USD 3897.0
Silver: Conference And 1 workshop: USD 3398.0
Bronze: Conference only: USD 2799.0
Workshops - Individual: USD 699.0

Speakers: Jim Cassella,Niels Plath ,Janet Nicholson ,Brigitte Robertson ,Mickey Matsumoto,Srinivas Rao ,Mark Smith ,Christopher Missling ,Venkatesha Murthy ,Eva Kohegyi ,Thomas Hudzik,David Putman ,Bill Potter ,Daniel Umbricht ,Steve Brannan ,Remy Luthringer ,Timothy Peters- Stickland ,Jerry Maguire,Adrian Preda ,Ottavio Vitolo ,Michael Gold ,Rich Daly,Michael Palfreyman

Time: 8:30 am to 5:30 pm

Additional details will be posted as soon as they are available.